Evidence map›Paper›PMID 40650051›Full record

ArticleInternational journal of molecular sciences2025

The Autophagy Inhibitor Bafilomycin Inhibits Antibody-Dependent Natural Killer Cell-Mediated Killing of Breast Carcinoma Cells.

Ákos M Bede, Csongor Váróczy, Zsuzsanna Polgár, Gergő Fazekas, Csaba Hegedűs, Endre Kókai, Katalin Kovács, László Virág

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Ákos M BedeDepartment of Medical Chemistry, Faculty of Medicine, University of Debrecen, Egyetem Tér 1, 4032 Debrecen, Hungary.
Csongor VáróczyDepartment of Medical Chemistry, Faculty of Medicine, University of Debrecen, Egyetem Tér 1, 4032 Debrecen, Hungary.
Zsuzsanna PolgárDepartment of Medical Chemistry, Faculty of Medicine, University of Debrecen, Egyetem Tér 1, 4032 Debrecen, Hungary.ORCID 0000-0002-7600-9672
Gergő FazekasDepartment of Medical Chemistry, Faculty of Medicine, University of Debrecen, Egyetem Tér 1, 4032 Debrecen, Hungary.
Csaba HegedűsDepartment of Medical Chemistry, Faculty of Medicine, University of Debrecen, Egyetem Tér 1, 4032 Debrecen, Hungary.ORCID 0000-0002-8575-691X
Endre KókaiDepartment of Medical Chemistry, Faculty of Medicine, University of Debrecen, Egyetem Tér 1, 4032 Debrecen, Hungary.ORCID 0000-0003-2035-8408
Katalin KovácsDepartment of Medical Chemistry, Faculty of Medicine, University of Debrecen, Egyetem Tér 1, 4032 Debrecen, Hungary.
László VirágDepartment of Medical Chemistry, Faculty of Medicine, University of Debrecen, Egyetem Tér 1, 4032 Debrecen, Hungary.ORCID 0000-0002-7099-6718

Funding

Development and Innovation Office grants OTKA K147482Hungarian Research Network 11-012
6 · The paper itself

Abstract

The resistance of breast cancer cells to therapeutic antibodies such as anti-HER2 trastuzumab can be overcome by engaging natural killer (NK) cells for killing antibody-binding tumor cells via antibody-dependent cellular cytotoxicity (ADCC). Here, we investigated how autophagy modulation affects trastuzumab-mediated ADCC in HER2-positive JIMT1 breast cancer cells and NK cells. Autophagy inducers (rapamycin and resveratrol) had no significant impact, but the inhibitor bafilomycin nearly abolished ADCC. Protection occurred when either cancer or NK cells were pretreated, indicating dual effects. Bafilomycin reduced phosphatidylserine externalization, the loss of plasma membrane integrity, caspase-3/7 activity, and DNA fragmentation. It downregulated pro-apoptotic

Indexed as

Antibody-Dependent Cell CytotoxicityAutophagyBreast NeoplasmsKiller Cells, NaturalMacrolidesApoptosisCell Line, TumorErb-b2 Receptor Tyrosine KinasesFemaleHumansTrastuzumabbafilomycin AERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesMacrolidesTrastuzumabantibody dependent cell-mediated cytotoxicityapoptosisautophagynatural killer celltrastuzumab

Identifiers

PMID40650051
PMCPMC12250358

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.